NDAORALTABLET
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XTRELUS is an oral tablet combination of guaifenesin (expectorant) and hydrocodone bitartrate (opioid antitussive) approved in April 2018 for cough suppression. It combines a mucolytic agent with an opioid to manage cough and mucus clearance in respiratory conditions. The drug targets patients requiring both cough suppression and secretion mobilization.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30/100), suggesting stable but not growth-oriented team sizes; focus likely on market maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggests limited active hiring around XTRELUS at the time of this analysis, indicating a mature team or potential staffing optimization. Career opportunity is best suited to candidates seeking established portfolio management rather than growth-stage expansion roles.
Brand ManagerField Sales Representative
Worked on XTRELUS at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.